Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

KYMR

Kymera Therapeutics Inc

May 01 • 04:00PM ET

36.24

Dollar change +2.62
Percentage change 7.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VBK VXF IBB IWO SCHA VTWO LABU

Index	RUT	P/E	-	EPS (ttm)	-2.52	Insider Own	11.38%	Shs Outstand	55.59M	Perf Week	2.93%
Market Cap	2.22B	Forward P/E	-	EPS next Y	-3.38	Insider Trans	-6.58%	Shs Float	54.38M	Perf Month	-3.72%
Income	-146.96M	PEG	-	EPS next Q	-0.72	Inst Own	89.82%	Short Float	17.84%	Perf Quarter	10.56%
Sales	78.59M	P/S	28.29	EPS this Y	-19.97%	Inst Trans	3.67%	Short Ratio	15.16	Perf Half Y	222.99%
Book/sh	7.11	P/B	5.10	EPS next Y	-11.65%	ROA	-24.93%	Short Interest	9.70M	Perf Year	15.12%
Cash/sh	6.11	P/C	5.93	EPS next 5Y	1.90%	ROE	-33.21%	52W Range	9.60 - 45.31	Perf YTD	42.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.18%	ROI	-31.05%	52W High	-20.02%	Beta	2.30
Dividend TTM	-	Quick Ratio	4.73	Sales past 5Y	241.22%	Gross Margin	95.46%	52W Low	277.50%	ATR (14)	1.95
Dividend Ex-Date	-	Current Ratio	4.73	EPS Y/Y TTM	12.49%	Oper. Margin	-210.62%	RSI (14)	51.22	Volatility	5.28% 5.06%
Employees	187	Debt/Eq	0.21	Sales Y/Y TTM	67.84%	Profit Margin	-186.99%	Recom	1.71	Target Price	51.07
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	59.24%	Payout	-	Rel Volume	1.00	Prev Close	33.62
Sales Surprise	14.17%	EPS Surprise	38.04%	Sales Q/Q	196.70%	Earnings	May 02 BMO	Avg Volume	639.66K	Price	36.24
SMA20	3.06%	SMA50	-6.36%	SMA200	40.67%	Trades		Volume	637,582	Change	7.79%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $32
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy	$40
Aug-03-22	Initiated	Goldman	Buy	$40
Jul-20-22	Initiated	SVB Leerink	Mkt Perform	$26
Apr-28-22	Initiated	Credit Suisse	Outperform	$63
Mar-10-22	Initiated	JP Morgan	Neutral	$44
Feb-10-22	Initiated	Wells Fargo	Overweight	$62
Sep-30-21	Initiated	Stifel	Buy	$80
Sep-30-21	Initiated	B. Riley Securities	Neutral	$67
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral	$65 → $80
May-21-21	Initiated	UBS	Buy	$80
Apr-14-21	Initiated	Berenberg	Buy

Show Previous Ratings

Today 07:00AM	Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -5.28%
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
07:00AM	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-08-24 07:00AM	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
10:00AM	Loading…
Mar-08-24 10:00AM	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-04-24 11:27PM	Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-23-24 11:59AM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 11:24PM	Q4 2023 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:35AM	Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-21-24 11:52PM	Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-15-24 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 (GlobeNewswire)
02:56AM	Loading…
Feb-10-24 02:56AM	Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-31-24 07:00AM	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference (GlobeNewswire)
Jan-24-24 12:20AM	Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-09-24 09:17AM	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) +7.80%
09:15AM	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-05-24 04:03PM	Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering (Investor's Business Daily)
06:00AM	Kymera Therapeutics Announces Pricing of $275 Million Public Offering (GlobeNewswire)
Jan-04-24 04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire) +18.86%
07:00AM	R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases (GlobeNewswire)
Jan-02-24 07:00AM	Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 (GlobeNewswire)
Dec-22-23 10:45AM	Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable? (TheStreet.com)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:00AM	Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 (GlobeNewswire) +7.33%
Dec-10-23 09:00PM	Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire)
11:13AM	Loading…
Dec-08-23 11:13AM	Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 (Zacks)
Dec-07-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi (GlobeNewswire) +7.20%
Nov-13-23 11:00AM	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine (GlobeNewswire)
Nov-07-23 09:05AM	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc (GuruFocus.com) +13.61%
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi (GlobeNewswire)
Oct-26-23 10:02AM	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know (Zacks)
07:00AM	Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 (GlobeNewswire)
Oct-19-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-18-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-16-23 07:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma (GlobeNewswire)
Oct-04-23 06:23AM	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-03-23 04:48PM	Why Shares of Kymera Therapeutics Jumped on Tuesday (Motley Fool) +14.30%
Sep-18-23 07:00AM	Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire)
Aug-28-23 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-03-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.07%
07:00AM	Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-27-23 07:00AM	Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 (GlobeNewswire)
Jul-09-23 09:09AM	Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-22-23 08:30AM	Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jun-14-23 02:30AM	Kymera Therapeutics STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials (GlobeNewswire)
Jun-09-23 06:00PM	Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 (GlobeNewswire)
03:00AM	Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress (GlobeNewswire)
Jun-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conference (GlobeNewswire)
May-29-23 12:24PM	Investors in Kymera Therapeutics (NASDAQ:KYMR) have seen notable returns of 95% over the past year (Simply Wall St.)
May-22-23 07:00AM	Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer (GlobeNewswire)
May-19-23 07:00AM	Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253 (GlobeNewswire)
May-18-23 07:00AM	Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium (GlobeNewswire)
May-14-23 02:57PM	7 Growth Stocks That Could Double Your Money in 2023 (InvestorPlace)
May-09-23 03:15PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -15.08%
07:00AM	Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-23 11:11AM	Some Shareholders Feeling Restless Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) P/S Ratio (Simply Wall St.)
Apr-11-23 07:00AM	Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4 (GlobeNewswire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-09-23 03:00PM	12 Small-Cap Stocks With Insider Buying (Insider Monkey)
Mar-03-23 11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Mar-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-24-23 02:53AM	Q4 2022 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.13%
Feb-23-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.17%
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-01-23 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23 (GlobeNewswire)
Jan-31-23 08:00AM	X-Chem and Kymera Expand Existing Partnership (Business Wire)
Jan-30-23 07:26AM	We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely (Simply Wall St.)
Jan-23-23 04:14AM	Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-17-23 06:27AM	Daily Vickers Top Buyers & Sellers for 01/17/2023 (Argus Research)
Jan-10-23 07:00AM	Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company (GlobeNewswire) +9.14%
Jan-09-23 12:00PM	All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy (Zacks)
Jan-04-23 07:00AM	Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jan-03-23 07:00AM	Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 (GlobeNewswire)
Dec-21-22 04:57PM	7 Perfect Presents to Gift Your 2023 Stock Portfolio (InvestorPlace)
Dec-20-22 10:33AM	Shareholders in Kymera Therapeutics (NASDAQ:KYMR) are in the red if they invested a year ago (Simply Wall St.)
Dec-15-22 10:27AM	Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474 (Zacks) -5.81%
Dec-14-22 04:09PM	Small Biotech Kymera Just Snagged Sanofi's Interest Here's Why (Investor's Business Daily) +14.58%
01:44PM	These Biotech Stocks Are the Nasdaq's Big Wednesday Winners (Motley Fool)
10:00AM	Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial (Benzinga)
07:57AM	Kymera's stock rallies as it plans to move treatment into Phase 2 studies next year (MarketWatch)
07:00AM	Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofis Decision to Advance KT-474 into Phase 2 Clinical Trials (GlobeNewswire)
Dec-12-22 10:00AM	Preclinical Data from Kymera Therapeutics Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting (GlobeNewswire) +8.11%
Dec-11-22 10:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-01-22 07:00AM	Kymera Therapeutics Provides Webcast Information for December 14 Investor Event (GlobeNewswire)
Nov-09-22 06:16AM	Kymera Therapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -8.24%
Nov-05-22 08:33AM	These Analysts Think Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Sales Are Under Threat (Simply Wall St.)
Nov-03-22 08:35AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +7.55%
07:05AM	Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Booth Bruce	Director	Mar 15 '24	Sale	40.46	71,764	2,903,336	806,697	Mar 15 07:23 PM
Booth Bruce	Director	Mar 14 '24	Sale	39.98	55,779	2,229,927	819,151	Mar 15 07:23 PM
Booth Bruce	Director	Mar 13 '24	Sale	42.23	139,255	5,880,415	828,830	Mar 13 07:52 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	115,090	4,859,993	4,676,075	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	24,165	1,020,422	828,830	Mar 13 07:53 PM
Booth Bruce	Director	Mar 12 '24	Sale	41.98	162,918	6,838,813	852,995	Mar 13 07:52 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	134,647	5,652,072	4,791,165	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	28,271	1,186,741	852,995	Mar 13 07:53 PM
Booth Bruce	Director	Mar 11 '24	Sale	42.85	51,184	2,193,148	881,266	Mar 13 07:52 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	42,302	1,812,586	4,925,812	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	8,882	380,562	881,266	Mar 13 07:53 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 04 '24	Sale	41.86	3,934	164,664	142,351	Mar 04 06:12 PM
Gollob Jared	Chief Medical Officer	Mar 04 '24	Sale	41.86	3,344	139,967	95,740	Mar 04 06:21 PM
Albers Jeffrey W.	Director	Feb 21 '24	Option Exercise	10.34	4,385	45,341	4,385	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 21 '24	Sale	39.05	4,385	171,227	0	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Option Exercise	10.34	615	6,359	615	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Sale	39.07	615	24,031	0	Feb 21 06:46 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Option Exercise	2.08	46,137	95,965	120,846	Feb 09 07:47 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Sale	35.50	46,137	1,638,071	74,709	Feb 09 07:47 PM
Albers Jeffrey W.	Director	Jan 23 '24	Option Exercise	10.34	10,000	103,400	10,000	Jan 23 07:37 PM
Albers Jeffrey W.	Director	Jan 23 '24	Sale	30.05	10,000	300,470	0	Jan 23 07:37 PM
Chiniara Ellen	Chief Legal Officer	Jan 04 '24	Sale	22.58	3,295	74,416	34,205	Jan 05 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jan 02 '24	Option Exercise	2.08	9,000	18,720	615,570	Jan 02 05:43 PM
Mainolfi Nello	Chief Executive Officer	Nov 03 '23	Option Exercise	2.08	20,000	41,600	606,570	Nov 06 06:00 PM
BVF PARTNERS L P/IL	Director	Nov 03 '23	Buy	14.07	197,699	2,781,407	2,656,191	Nov 06 06:07 PM
BVF PARTNERS L P/IL	Director	Nov 02 '23	Buy	11.64	216,406	2,519,918	2,552,306	Nov 06 06:07 PM
Mainolfi Nello	Chief Executive Officer	Aug 08 '23	Option Exercise	2.08	12,000	24,960	586,570	Aug 08 04:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 02 '23	Option Exercise	2.08	10,000	20,800	115,035	Jun 02 02:17 PM

Open in Screener

IRON

Disc Medicine Inc

May 01 • 04:00PM ET

28.53

Dollar change +0.69
Percentage change 2.48	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

IRON Disc Medicine Inc daily Stock Chart

Held by: VTI VXF IWM IBB VHT LABU VTWO IWO DWAS SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.50	Insider Own	48.05%	Shs Outstand	24.68M	Perf Week	4.51%
Market Cap	704.12M	Forward P/E	-	EPS next Y	-5.26	Insider Trans	-13.24%	Shs Float	12.82M	Perf Month	-10.94%
Income	-76.43M	PEG	-	EPS next Q	-1.01	Inst Own	51.82%	Short Float	14.93%	Perf Quarter	-56.61%
Sales	0.00M	P/S	-	EPS this Y	-26.02%	Inst Trans	4.10%	Short Ratio	4.02	Perf Half Y	-36.89%
Book/sh	14.87	P/B	1.92	EPS next Y	-22.14%	ROA	-26.90%	Short Interest	1.91M	Perf Year	-17.57%
Cash/sh	14.60	P/C	1.95	EPS next 5Y	-	ROE	-29.30%	52W Range	25.60 - 77.60	Perf YTD	-50.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-21.20%	52W High	-63.23%	Beta	0.43
Dividend TTM	-	Quick Ratio	25.96	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.45%	ATR (14)	2.59
Dividend Ex-Date	-	Current Ratio	17.06	EPS Y/Y TTM	50.94%	Oper. Margin	0.00%	RSI (14)	30.18	Volatility	6.07% 5.95%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	57.11
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	19.77%	Payout	-	Rel Volume	0.93	Prev Close	27.84
Sales Surprise	-	EPS Surprise	-16.70%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	476.24K	Price	28.53
SMA20	-3.33%	SMA50	-42.43%	SMA200	-46.05%	Trades		Volume	437,334	Change	2.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

Apr-02-24 02:24PM	Disc Medicine (IRON) Down on Mixed Results From AURORA Study (Zacks) -6.36%
Apr-01-24 04:19PM	Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study (Investor's Business Daily) -45.05%
08:00AM	Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-23-24 05:31AM	Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance (GuruFocus.com)
Mar-21-24 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
04:30PM	Loading…
Mar-06-24 04:30PM	Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer (GlobeNewswire)
Feb-20-24 08:30AM	Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (GlobeNewswire)
Feb-09-24 09:00AM	Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera (GlobeNewswire)
Feb-07-24 08:00AM	Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer (GlobeNewswire)
Jan-03-24 05:00PM	Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:30PM	Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board (GlobeNewswire)
Dec-15-23 03:01PM	Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON) (GuruFocus.com)
Dec-11-23 08:30PM	Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
12:00PM	Loading…
12:00PM	Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-23 07:06AM	Insider Sell Alert: CFO Joanne Bryce Sells 2,541 Shares of Disc Medicine Inc (IRON) (GuruFocus.com) +5.98%
Nov-14-23 04:44PM	Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin (GlobeNewswire)
Nov-13-23 09:55AM	How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17% (Zacks)
Nov-09-23 09:34AM	Disc Medicine Inc (IRON) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
08:30AM	Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates (GlobeNewswire)
Oct-23-23 09:15AM	Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce (GlobeNewswire)
Oct-03-23 08:30AM	Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers (GlobeNewswire)
Sep-20-23 04:30PM	Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera (GlobeNewswire)
Aug-30-23 04:15PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 11:20AM	Stock Screen Finds These Growth Stocks Outperforming The S&P 500 (Investor's Business Daily)
Aug-11-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
08:00AM	Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
09:00AM	Loading…
Jul-27-23 09:00AM	Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Jul-25-23 09:55AM	Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-22-23 04:15PM	Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-20-23 07:33PM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +7.20%
Jun-13-23 10:39PM	Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-12-23 04:00PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.92%
01:59AM	4 big analyst picks: Adobe a buy on AI hopes, says Wells Fargo (Investing.com)
Jun-09-23 04:13PM	Why Perfectly Rated Disc Medicine, With A 287% Move This Year, Just Put Up Another Big Gain (Investor's Business Daily) +15.76%
07:00AM	Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
Jun-01-23 03:10PM	Why Shares of Disc Medicine Opco Climbed This Week (Motley Fool) +7.06%
May-31-23 04:00PM	Disc Medicine to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +12.01%
May-15-23 07:00AM	Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-11-23 10:15AM	Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
May-10-23 10:23AM	Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season? (Zacks) +5.24%
May-05-23 08:50AM	Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
May-04-23 12:00PM	Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know (Zacks)
Apr-28-23 05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
Apr-21-23 08:30AM	Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +11.57%
Apr-19-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
Apr-13-23 11:00AM	Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-31-23 07:00AM	Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-30-23 07:05AM	Disc Medicine Opco Inc (NASDAQ:IRON) most popular amongst private equity firms who own 48% of the shares, institutions hold 21% (Simply Wall St.)
Mar-21-23 07:00AM	Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Feb-16-23 08:00AM	Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia (GlobeNewswire)
Feb-14-23 06:30AM	Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs (GlobeNewswire)
Feb-08-23 04:00PM	Disc Medicine to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 07:00AM	Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis (GlobeNewswire)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
White William Richard	Director	Apr 11 '24	Option Exercise	4.91	2,560	12,581	2,560	Apr 15 06:27 PM
White William Richard	Director	Apr 11 '24	Sale	31.80	2,560	81,407	0	Apr 15 06:27 PM
Savage William Jacob	Chief Medical Officer	Apr 10 '24	Option Exercise	2.65	21,870	57,956	43,405	Apr 11 05:02 PM
Bitterman Kevin	Director	Mar 05 '24	Sale	73.50	26,157	1,922,540	677,503	Mar 07 04:40 PM
Bitterman Kevin	Director	Jan 23 '24	Sale	67.65	102,500	6,934,125	198,326	Jan 25 04:33 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 23 '24	Sale	67.65	102,500	6,934,125	198,326	Jan 25 04:31 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 23 '24	Sale	67.65	47,500	3,213,375	1,402,186	Jan 25 04:31 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 10 '24	Sale	64.00	30,000	1,920,000	1,449,686	Jan 12 05:12 PM
Bitterman Kevin	Director	Jan 10 '24	Sale	64.00	20,000	1,280,000	786,160	Jan 12 05:12 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 10 '24	Sale	64.00	20,000	1,280,000	786,160	Jan 12 05:12 PM
Quisel John D	Chief Executive Officer	Dec 29 '23	Option Exercise	1.01	2,700	2,727	2,700	Jan 03 04:05 PM
Bryce Joanne	Chief Financial Officer	Dec 27 '23	Option Exercise	9.86	3,000	29,580	5,500	Dec 29 04:15 PM
Ashiya Mona	Director	Dec 18 '23	Option Exercise	38.00	1,724	65,512	1,724	Dec 20 06:16 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '23	Option Exercise	38.00	1,724	65,512	1,724	Dec 20 06:28 PM
Ashiya Mona	Director	Dec 18 '23	Sale	59.24	1,724	102,130	0	Dec 20 06:16 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '23	Sale	59.24	1,724	102,130	0	Dec 20 06:28 PM
ORBIMED ADVISORS LLC	Director	Dec 14 '23	Sale	56.75	433,200	24,584,100	224,405	Dec 15 06:04 PM
Ashiya Mona	Director	Dec 14 '23	Sale	56.75	433,200	24,584,100	224,405	Dec 15 06:09 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 14 '23	Sale	58.28	30,825	1,796,437	1,479,686	Dec 14 08:13 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 14 '23	Sale	58.28	20,549	1,197,567	806,160	Dec 14 08:13 PM
Bitterman Kevin	Director	Dec 14 '23	Sale	58.28	20,549	1,197,567	806,160	Dec 14 08:14 PM
ORBIMED ADVISORS LLC	Director	Dec 14 '23	Sale	57.73	200	11,546	727,807	Dec 14 05:44 PM
Ashiya Mona	Director	Dec 14 '23	Sale	57.73	200	11,546	727,807	Dec 14 05:40 PM
Ashiya Mona	Director	Dec 13 '23	Sale	58.56	106,700	6,248,352	281,505	Dec 14 05:40 PM
ORBIMED ADVISORS LLC	Director	Dec 13 '23	Sale	58.56	106,700	6,248,352	281,505	Dec 14 05:44 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 13 '23	Sale	60.00	5,323	319,357	1,510,511	Dec 14 08:13 PM
Bitterman Kevin	Director	Dec 13 '23	Sale	60.00	3,548	212,865	826,709	Dec 14 08:14 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 13 '23	Sale	60.00	3,548	212,865	826,709	Dec 14 08:13 PM
White William Richard	Director	Dec 12 '23	Option Exercise	6.08	33,511	203,883	33,511	Dec 14 04:15 PM
Bryce Joanne	Chief Financial Officer	Dec 12 '23	Option Exercise	2.65	2,500	6,625	5,000	Dec 14 04:15 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 12 '23	Sale	62.80	77,951	4,895,032	1,515,834	Dec 14 08:13 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 12 '23	Sale	62.80	51,967	3,263,328	830,257	Dec 14 08:13 PM
Bitterman Kevin	Director	Dec 12 '23	Sale	62.80	51,967	3,263,328	830,257	Dec 14 08:14 PM
White William Richard	Director	Dec 12 '23	Sale	63.21	33,511	2,118,239	0	Dec 14 04:15 PM
ORBIMED ADVISORS LLC	Director	Dec 12 '23	Sale	60.16	27,300	1,642,368	295,605	Dec 14 05:44 PM
Ashiya Mona	Director	Dec 12 '23	Sale	60.16	27,300	1,642,368	295,605	Dec 14 05:40 PM
Bryce Joanne	Chief Financial Officer	Dec 12 '23	Sale	65.22	2,500	163,062	2,500	Dec 14 04:15 PM
Bryce Joanne	Chief Financial Officer	Dec 05 '23	Option Exercise	1.01	1,281	1,294	5,041	Dec 07 04:15 PM
Bryce Joanne	Chief Financial Officer	Dec 05 '23	Sale	56.00	2,541	142,299	2,500	Dec 07 04:15 PM
Khara Rahul	General Counsel	Nov 22 '23	Option Exercise	14.69	10,000	146,900	10,000	Nov 27 04:15 PM
Khara Rahul	General Counsel	Nov 22 '23	Sale	51.73	10,000	517,333	0	Nov 27 04:15 PM
Khara Rahul	General Counsel	Nov 14 '23	Option Exercise	14.69	4,900	71,981	4,900	Nov 15 05:00 PM
Khara Rahul	General Counsel	Nov 14 '23	Sale	50.61	4,900	248,012	0	Nov 15 05:00 PM
Khara Rahul	General Counsel	Nov 03 '23	Option Exercise	14.69	100	1,469	100	Nov 07 06:22 PM
Khara Rahul	General Counsel	Nov 03 '23	Sale	50.00	100	5,000	0	Nov 07 06:22 PM
Atlas Venture Fund X, L.P.	10% Owner	Sep 16 '23	Sale	53.22	2,115	112,560	1,593,785	Sep 18 04:59 PM
Atlas Venture Fund X, L.P.	10% Owner	Sep 15 '23	Sale	53.16	260,894	13,869,125	1,595,900	Sep 18 04:59 PM
Atlas Venture Fund X, L.P.	10% Owner	Sep 14 '23	Sale	53.05	94,440	5,010,042	1,856,794	Sep 18 04:59 PM
Bryce Joanne	Chief Financial Officer	Sep 11 '23	Option Exercise	9.86	2,500	24,650	3,760	Sep 13 04:15 PM
Bryce Joanne	Chief Financial Officer	Sep 01 '23	Option Exercise	2.65	1,000	2,650	2,260	Sep 05 04:16 PM
Bryce Joanne	Chief Financial Officer	Sep 01 '23	Sale	52.99	1,000	52,990	1,260	Sep 05 04:16 PM
Savage William Jacob	Chief Medical Officer	Aug 21 '23	Option Exercise	2.65	3,000	7,950	3,000	Aug 22 04:06 PM
Atlas Venture Fund X, L.P.	10% Owner	Aug 15 '23	Sale	52.40	111,069	5,820,016	1,951,234	Aug 16 06:55 PM
Bitterman Kevin	Director	Aug 15 '23	Sale	52.40	72,931	3,821,584	882,224	Aug 17 04:13 PM
Atlas Venture Fund X, L.P.	10% Owner	Aug 15 '23	Sale	52.40	72,931	3,821,584	882,224	Aug 16 06:55 PM
Savage William Jacob	Chief Medical Officer	Aug 15 '23	Sale	52.95	7,672	406,235	0	Aug 16 04:15 PM
Atlas Venture Fund X, L.P.	10% Owner	Aug 14 '23	Sale	52.59	175,000	9,203,600	2,062,303	Aug 16 06:55 PM
Savage William Jacob	Chief Medical Officer	Aug 09 '23	Sale	49.83	8,269	412,064	7,672	Aug 11 04:15 PM
Bryce Joanne	Chief Financial Officer	Aug 01 '23	Option Exercise	1.01	4,521	4,566	5,781	Aug 03 04:18 PM
Bryce Joanne	Chief Financial Officer	Aug 01 '23	Sale	49.91	4,521	225,633	1,260	Aug 03 04:18 PM
MacDonald Brian Richard	Chief Innovation Officer	Jun 30 '23	Sale	45.05	4,324	194,778	12,876	Jun 30 06:29 PM
MacDonald Brian Richard	Chief Innovation Officer	Jun 29 '23	Sale	45.79	5,100	233,509	17,200	Jun 30 06:29 PM
Bryce Joanne	Chief Financial Officer	Jun 28 '23	Option Exercise	1.01	7,880	7,959	11,332	Jun 30 04:49 PM
Novo Holdings A/S	10% Owner	Jun 28 '23	Sale	46.10	1,250,000	57,625,000	1,090,772	Jun 28 05:04 PM
Bryce Joanne	Chief Financial Officer	Jun 28 '23	Sale	49.95	10,072	503,114	1,260	Jun 30 04:49 PM
MacDonald Brian Richard	Chief Innovation Officer	Jun 28 '23	Sale	49.96	5,100	254,795	22,300	Jun 30 06:29 PM
Savage William Jacob	Chief Medical Officer	Jun 28 '23	Sale	49.98	4,384	219,114	15,941	Jun 30 04:12 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

KYMR

Kymera Therapeutics Inc

IRON

Disc Medicine Inc

Upgrade your FINVIZ experience